Immunohistochemistry in Breast Pathology- Brief Overview of the Technique and Applications in Breast Pathology
|
|
- Victor Sutton
- 5 years ago
- Views:
Transcription
1 SMGr up Immunohistochemistry in Breast Pathology- Brief Overview of the Technique and Applications in Breast Pathology Bhanumathi K Rao 1 * 1 Department of Biochemistry, JSS Medical College, a constituent of JSS University, India *Corresponding author: Nandini Manoli, Department of Pathology, JSS Medical College, a constituent of JSS University, Mysore, Karnataka, India, nandinimanoli65@gmail.com Published Date: April 30, 3016 INTRODUCTION AND TECHNICAL ASPECTS Immunohistochemistry (IHC) is a powerful technique by which specific antigens are identified in Formalin-Fixed, Paraffin-Embedded (FFPE) tissues. The method is based on antigen-antibody interaction (Taylor and Burns, 1974). The technique is widely used in breast cancer diagnosis and prognosis, and its applications continue to be extended because of its ease of use, comparative low cost, reliability, and versatility. In IHC an antigen-antibody reaction is visualized through light microscopy by means of a color signal which is produced by labeling or tagging the antibody by various methods. The morphology of the tissue around the specific antigen is clearly visualized by counter staining usually with Hematoxylin (blue). Results of stained IHC markers are reported semi quantitatively and have been used widely by pathologists for prognostication of breast tumors and also for diagnosis and differentiation of certain lesions of the breast. 1
2 2
3 STEP1: FIXATION Fixation is a very crucial factor for optimal immunostaining. The tissues must be promptly and adequately fixed and well processed for crisp, clear and unambiguous results. Problems of interpretation can arise due to under fixation due to elution of the stain or over fixation which causes masking of antigen sites, and hence false negative results. Optimal times can be determined by the individual laboratory. A General Guideline for the Various Types of Samples is Mastectomy specimens and core biopsies: The tissue is fixed immediately in neutral buffered formalin. Tissue must not be allowed to dry. The fixation time is paramount, requiring between 6 and 48 hours. Breast FNAC/Cytology smears: Must be dropped into 10 %neutral buffered formalin and fixed for10 minutes. Alternately centrifuge the fluid to make a pellet and fix similarly to tissue. Ether alcohol or acetone may be poured on to fresh smears on the slide. STEP 2: ANTIGEN RETRIEVAL Formalin fixation is good for retaining morphology of the tissue, but causes masking of several epitopes. However these can be unmasked by antigen retrieval which is the next step. The FFPE tissue should be cut into 3- to 4-micron thin sections and cut on to glass slide coated with an adhesive, the most popular being Poly L Lysine (PLL) or alternately onto APES coated slides. Two methods are available, Heat retrieval Enzyme retrieval Heat Retrieval The most common antigen retrieval technique to restore the tertiary structure is heating tissue sections in water or buffered solutions (e.g., citrate or EDTA buffer). Microwave, pressure cooker, water bath and now automated pressure cooking based technology are available for heat retrieval. Enzyme digestion By trypsin or protease is the alternative method. 3
4 STEP 3: ANTIGEN-ANTIBODY INTERACTION AND LABELING/ DETECTION Basically two methods are available, the direct and the indirect methods, the basic difference being that the direct method uses labeled monospecific antibody and the indirect uses unlabeled primary antibodies. Direct Method The labeled antibody reacts directly with antigen (Figure 1) (a) Biotin labeled antigen-specific primary antibody (b) Biotin binds to avidin/streptavidin. This amplifies the staining. c) Color visualization is achieved through enzymatic reaction of horseradish peroxidase/ alkaline phosphatase. Advantage Short, quick and easy Disadvantages Very specific labeled antibodies have to be manufactured and tested against each antigen Poor signal amplification, hence not sensitive Indirect Method Here two layers of antibodies are utilized (Figure 1 and Figure 1c). (a) The primary antibody is unlabeled and reacts with the tissue antigen. (b) The secondary antibody is biotin-labeled and binds to primary antibody. (c) Secondary antibody is raised to the antibody of the same species which produced the primary. Advantage Increases versatility because the same primary antibody can be used with different secondary antibodies. Sensitive due to signal amplification, because the primary antibody can react with different antigenic sites. Also this allows higher dilution of the primary-reduces cost and nonspecific background staining Further developments are 4
5 Unlabeled Method Here the secondary antibody acts as bridge between the primary antibody and the enzyme detection complex. The peroxidase- antiperoxidase technique was the first of these methods to be used. It is a multistep procedure, using unlabeled primary and secondary antibodies and preformed enzyme detection complexes consisting of enzymes-peroxidase antiperoxidase/alkaline phosphatase linked with Avidin/Streptavidin (glycoproteins) and the vitamin Biotin which binds easily to both enzymes and antibodies. Advantage Signal amplification is increased in this multistep process Figure 1: Schematic diagram of Immunohistochemical techniques. (a) Direct method: the antigen-specific primary antibody is biotin labeled. Biotin binds to avidin/streptavidin. Color visualization is achieved through enzymatic reaction of horseradish peroxidase/alkaline phosphatase. (b) Indirect method: the antigen-specific primary antibody is unlabeled. The secondary, biotinlabeled antibody binds to primary antibody. Visualization is achieved accordingly through avidin/ streptavidin and peroxidase/alkaline phosphatase complexes. The indirect method increases versatility because unlabeled primary antibodies can be used. 5
6 (c) Indirect method with polymerchain detection system. Biotin and avidin/streptavidin are replaced by a polymer backbone. Indirect Method with Polymer Chain Detection System Biotin and avidin/streptavidin are replaced by a labeled polymer chain, allowing for increased sensitivity and specificity. Multiple secondary antibodies and enzymes conjugate with a polymer backbone (Figure 1c). These are highly sensitive as well as specific and hence there is much less nonspecific background staining when compared to enzyme detection techniques. Using two different colors in one tissue section is also possible by combining two immunoenzymatic systems or one immunoenzymatic system with different substrates. STEP 4: VISUALIZATION In the previous step active enzymes such as horseradish peroxidase or calf intestine alkaline phosphatase are added to the tissue sections to tag or label the biotin, avidin/streptavidin labeled antibodies so that they can be visualized. These in turn react with a chromogen such as DAB (3, 3 diaminobenzidine tetrahydrochloride) or AEC (3-amino-9-ethylcarbazole) which gets oxidized by the enzyme, so that a colored product is formed. A brown color is obtained when DAB is used as a chromogen and a red product when AEC is used. 6
7 QUALITY CONTROL IN IMMUNOHISTOCHEMISTRY Quality Control is imperative to standardize the IHC protocol in order to ensure that IHC staining is sensitive and specific and that the results are reproducible. Positive and negative controls should be used with every run. Tissue samples containing the antigen to be detected may 7
8 be identified for use as both positive and negative control. Sections are cut and stained along with the sample to be tested. For the negative control, the primary antibody is replaced by nonbinding Immunoglobulin from the same species (Figure 2 & Figure 3). Figure 2: Smooth muscle actin highlighting the myoepithelial layer of benign ducts. Figure 3: Negative SMA immunostain in a case of invasive carcinoma. The smooth muscle around the blood vessels has taken up the stain, acting as an internal control. False-Negative Results These are mainly due to faulty pre analytical procedures: Improper tissue fixation 8
9 Improper processing Improper pretreatment Troubleshooting Buffered neutral Formalin is mandatory for fixation; ER gives optimal reaction with this fixative. All reagents to be checked for ph before use and maintained at 7.2. If a Formalin alternative is used, it must be validated against NBF, laboratory director assuming responsibility for the validity of these assay results. False-positive results can occur through nonspecific background staining. Ionic binding of antibodies to charged connective tissue elements, e.g., collagen fibers. To avoid this, it is recommended that the tissue be incubated with normal serum of the same species as the secondary antibody (blocking). Endogenous enzyme activity must be blocked-taking into account the fixation and retrieval method-to further avoid false-positive reactions. Undissolved precipitates of chromogen or counter stain can also be mistaken for a positive reaction. Validation of IHC methodologies can be achieved by: 1. Participation in quality assurance (proficiency testing) programs. 2. Staining various tissue and tumor types to determine sensitivity and specificity 3. Comparing staining results of different antibodies that recognize similar proteins [1-4]. Prognostic and predictive ER, PR Her-2- neu ER/ PR: It is routine practice to evaluate all invasive breast cancers for Estrogen Receptor (ER) and Progesterone Receptor (PR) status, in order to predict prognosis and responsiveness to endocrine treatment should cancer recur after initial treatment. Earlier performed by biochemical assay, Immunohistochemistry is now the standard method as IHC has been proven to be equal and in fact, superior in predicting tamoxifen response in a clinically relevant manner. Levels as low as 1% positive staining of the carcinoma cells are associated with significant clinical response to hormonal therapy. 1. Prognostic role ER/PR serves as good biomarkers for treatment decisions 2. Predictive role 3. Role in pre-invasive stage 9
10 Prognostic role: ER/PR positive tumors have better prognosis than those which are negative, especially if both ER and PR are positive. These tumors are hormone responsive Adjuvant chemotherapy and endocrine treatment prevent or delay recurrence in ER positive cancers ER/PR serves as good biomarkers for treatment decisions Predictive Role St Gallen treatment guidelines partition breast cancer into 3 endocrine groups, which predicts the type of response depending on the hormone receptor status. Standardized, reproducible ER/ PR staining is necessary to classify patients into these groups. 1. Responsive high- 10% positivity 2. Response uncertain 3. Response Low (1%-9%) 4. Non responsive none (0) ER-negative invasive breast cancers do not benefit from endocrine therapy. PR status has an independent predictive role irrespective of the ER status especially among premenopausal women [5-7]. 1% of staining of tumor cell nuclei has a predictive value 10. Greater than 1% of carcinoma cells positive for PR corresponding to an ALL red score of more than 2 is associated with a disease free interval and overall survival for those who receive adjuvant chemotherapy Hormone Receptor IHC in DCIS: Immunohistochemical staining for ER in DCIS, lacking associated invasive carcinoma, has an emerging role in estimating potential tamoxifen benefit. Adjuvant tamoxifen in these patients reduced both ipsilateral recurrence and new contra lateral cancers [5]. Guidelines for ER/PR testing: ER and PR status should be determined on: All newly diagnosed invasive breast cancers. At least one and preferably the largest of multiple synchronous tumors. Breast recurrences (to ensure that prior negative results of ER and/or PR were not false negatives and to evaluate the specimen for biologic changes since the previous testing) Newly diagnosed cases of DCIS also being analyzed for receptor content 10
11 TECHNICAL ASPECTS Preanalytic Immediate fixation after resection is ideal Fixative: Buffered Neutral Formalin solution only. ph to be maintained at 7.2 Time of fixation more than 6 and less than 72 hours, time to be recorded. Check ph of all reagents before assay If tumor comes from a remote location, it should be bisected neatly through the tumor on removal and sent to the laboratory immersed in a sufficient volume of NBF. Cold ischemia time, fixative type, and time the sample was placed in NBF must be recorded. Time tissue is removed from patient, time tissue is placed in fixative, duration of fixation, and fixative type must be recorded and noted on accession slip or in report. Storage of slides for more than 6 weeks before analysis is not recommended for Her-2 staining Analytic Ideally known negative, intermediate positive and strong positive controls to be run or at least positive and negative controls to be run with each run Endometrial tissue with known receptor content may be used as external control Internal control from normal breast tissue to be run: It should show heterogenous staining of the luminal cells with weak, moderate and strong intensity. If not, i.e if the staining is homogenous and weak, it indicates low sensitivity of the assay and will lead to false negative interpretation of the test. Normal breast tissue acts as a built-in negative control, the myoepithelial cells and the stromal cells being negative for receptor content. Check controls before reading the slides - assay to be rejected if controls do not work and repeated under standard test conditions till desired till acceptable staining is achieved Analyze the invasive component. Choose non necrotic areas. When there is no normal breast epithelium and henceno built in control, the pathologist must exercise judgment as to whether the assay can be interpreted based on the level of ER and/ or PR positivity of the tumor cells, the histologic type of the tumor, the fixation status ofthe tumor, and the status of external controls. If a tubular, mucinous, or lobular morphology or a tumour with Nottingham score of 1 tests 11
12 ER /PR negative contrary to expectations, retesting on another bit of tissue or sending the specimen to referral laboratory for confirmation may be necessary (Figure 4). Figure 4: IHC in a case of lobular carcinoma breast. ER, Cytokeratin and CK7 positivity with negative E-cadherin confirmed a diagnosis of metastatic lobular in this patient who presented with abdominal metastasis at a later date. Post Analytic Participating in proficiency testing programs; interlaboratory comparison. Guidelines for reporting receptor status: Reporting ER/PR, (Figure 5 & Figure 6) Nuclear positivity Report contains percentage positivity and intensity The percentage of tumor cells is quantified by counting cells manually. Image analysis may also be used. Cytology specimen: At least 100 cells should be counted to estimate the percentage. The intensity of staining is reported as weak, Moderate, or strong (1+,2+,3+) in comparison with the positive controls and should be indicative of the average staining intensity of the tumour nuclei on the entire slide. Receptor positive:1% positive tumor nuclei using internal (normal epithelial elements) and external controls 12
13 Receptor negative: When less than 1% of tumor cells stain for ER or PR Receptor uninterpretable: Tissues negative for ER/PR that are without intrinsic elements (normal breast epithelium) should be repeated using another tumor block or another tumor specimen and reported as uninterpretable rather than as negative. Figure 5: An example of strong ER positive staining of almost 98% of the nuclei. By the Allred score, this would qualify for a proportion score of 5 and an intensity score of 3+. Figure 6: PR positive staining of almost 99% of the nuclei. This would qualify for a proportion score of 5 and an intensity score of
14 The reason for the uninterpretable result should be specified. This usually occurs when sample preanalytic guidelines were not met with, for example: Use of alcoholic fixatives for needle biopsies or cytology samples Fixatives other than 10% Neutral Buffered Formalin (NBF) Sub optimal fixation-under or over fixation (less than 6 hours than 72 hours) Delay in initiation of fixation by more than 1 hour Samples treated with acids as part of a decalcification procedure. Tissues with unsatisfactory staining of controls. Staining of adjacent normal breast indicates that the assay is too sensitive-leads to false positive Samples on unstained slides for >6 weeks prior to staining Needle/core biopsies with crush artifact (eg, under fixed sample -fixation for less than 6 hours), and an alternative potential sample for retesting should be suggested, if appropriate. ER/ PR negativity in histological types expected to be ER/PR-positive: Tubular, lobular, and mucinous histologic types or tumors with a Nottingham score of 1 being ER/PR negative. The statement should convey that such histologic subtypes or Nottingham score in most cases test ER/PR positive. HER-2/neu: (Human epidermal growth factor) (Figure 7). Oncogene which gives membranous staining of the carcinoma cells. Its presence signifies bad prognosis. Biomarker for Herceptin sensitivity (trastuzumab) monoclonal antibody against the HER-2 receptor) Its presence denotes resistance to tamoxifen Identification is by IHC. Should be performed on all newly diagnosed cases of primary breast cancer On subsequent metastatic site if any and if tissue is available. An FDA-approved IHC kit should be used preferentially. Manual Interpretation with Conventional Microscopy: Interpretation of Her 2 neu: Staining: membrane 14
15 Normal breast tissue should not take up stain. Can be done on core biopsies. (Concordance with resection is 85 to 90%) Only invasive carcinoma is scored; scoring is semi quantitative to be clinically relevant. Evaluate the HER2 sections for estimation of the percentage of tumor cells showing membrane staining at low power first, 4x magnification. The majority of strongly positive cases will be obvious at 4x magnification. In situ breast cancer cells should not be scored and has no relevance. To verify the percentage of stained tumor cells and completeness of membrane staining, use 10x magnifications. Well-preserved and well-stained areas of the specimen should be used to make a determination of the percent of positive infiltrating tumor cells. If determination of equivocal 1+/2+ cases is difficult using 10x magnification, confirm score using 20x or 40x magnification. If there is complete membrane staining at a weak to moderate intensity in greater than 10% of the tumor cells, the score of the specimens is 2+. This is usually accompanied by incomplete membrane staining of the majority of the remaining tumor cells. In the majority of 3+ cases, staining is usually homogeneous with approximately 80% of the tumor cells positive with intense uniform staining HER2 test indeterminate may be reported if technical issues prevent one or both tests from being reported as positive, negative, or equivocal such as Inadequate specimen handling Artifacts (crush or edge artifacts) that make interpretation difficult Analytic testing failure Multiple scoring systems have been used by various authors to predict treatment such as the H score, Allred score, or quick score using the percentage and intensity measurements. The Allred score which gives both percentage and intensity is recommended by the food and drug administration Dako Cytomation Hercep Test and the Ventana CB1are approved by Food and Drug Administration [5,8]. 15
16 Figure 7: HER 2 neu stain. Other Prognostic Indicators Ki-67 (MIB-1) stains the nuclei of cell in the G-phase and hence is a proliferation marker, the percentage of stained nuclei expressed as the proliferation index. It is being increasingly used as part of the prognostic panel as a low proliferation index indicates slower tumor growth and therefore better prognosis, whereas a high Ki-67 indicate indicates bad prognosis [5]. SUMMARY AND CONCLUSION To summarize, Immunohistochemistry is a technique that has wide applications in the field of Breast pathology, ranging from diagnostic, prognostic and therapeutic uses and also as a research tool. The reason for its popularity is that it is a fairly inexpensive, reliable and versatile method requiring relatively basic infrastructure and can be used not only in breast resection specimens but also in core biopsies and cytological specimens. The results are reported semi quantitatively and help to categorize breast carcinomas into therapeutic groups predicting response to therapy. Apart from prognostic assays, other diagnostic difficulties IHC can help resolve are to recognize micro-invasion, differentiation between usual and atypical hyperplasia, benign mimickers of malignancy from malignant conditions, to sub type breast tumors and determine the origin of intra and extra mammary metastasis. The last, though there is no specific marker for mammary tissue, is possible by using a panel of markers. IHC has also become an important research tool and is widely used in microarrays to determine various breast cancer histologic subtypes and phenotypes. As a concluding remark, the use and interpretation of immunohistochemistry should be done in the light of the clinical history, radiologic findings, and histologic characteristics of the tumors. A panel based approach used in conjunction with standard Hematoxylin-eosinstain is probably most successful. 16
17 References 1. Dabbs DJ. Diagnostic Immunohistochemistry: Theranostic and Genomic Applications, 4th edn. Saunders: Philadelphia, PA Schacht V, Kern JS. Basics of immunohistochemistry. J Invest Dermatol. 2015; 135: e Taylor CR. Introduction to Immunohistochemistry. 1: Shi SR, Liu C, Taylor CR. Standardization of immunohistochemistry for formalin-fixed, paraffin-embedded tissue sections based on the antigen-retrieval technique: from experiments to hypothesis. J Histochem Cytochem. 2007; 55: Yeh IT, Mies C. Application of immunohistochemistry to breast lesions. Arch Pathol Lab Med. 2008; 132: Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thürlimann B, Senn HJ, et al. First-select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol. 2006; 17: Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ; et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer Ann Oncol. 2005; 16: Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31:
# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer
#1034 - Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer Richard W. Cartun, MS, PhD Andrew Ricci, Jr, MD Department of Pathology Hartford
More informationDr. dr. Primariadewi R, SpPA(K)
Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty
More informationBrief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies
Brief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies Victoria Sujoy, MD, Mehrdad Nadji, MD, and Azorides R. Morales, MD From
More informationQuality assurance and quality control in pathology in breast disease centers
Quality assurance and quality control in pathology in breast disease centers Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 1 st IBDC, 28 th January, 2011
More informationTemplate for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast Version: Template Posting Date: January 2018 Includes requirements from the 2017 CAP Accreditation
More informationOptimal algorithm for HER2 testing
Optimal algorithm for HER2 testing The revised definition of IHC 2+ (equivocal) is invasive breast cancer with Weak to moderate complete membrane staining observed in >10% of tumor cells. (see Figure 1
More informationReporting of Breast Cancer Do s and Don ts
Reporting of Breast Cancer Do s and Don ts 7 th SGH Annual Breast Pathology Course Professor Michael Bilous Conjoint Professor Western Sydney University Consultant Pathologist, Australian Clinical Labs,
More informationProduct Introduction
Product Introduction Product Codes: HCL026, HCL027 and HCL028 Contents Introduction to HER2 2 HER2 immunohistochemistry 3 Cell lines as controls 5 HER2 Analyte Control DR IHC 7 HER2 Analyte Control DR
More informationDiagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Pathology. AGO e. V. in der DGGG e.v. sowie in der DKG e.v.
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Pathology Pathology Versions 2004 2017: Blohmer / Costa / Fehm / Friedrichs / Huober / Kreipe / Lück / Schneeweis / Sinn /
More informationWelcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016
HER2 TESTING DIAGNOSTIC ACCURACY Can t We Finally Get It Right? Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Seattle, Washington Clinical Professor of Pathology University
More informationImmunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
More informationResearch Article Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
SAGE-Hindawi Access to Research International Breast Cancer Volume 20, Article ID 47957, 4 pages doi:0.406/20/47957 Research Article Stromal Expression of CD0 in Invasive Breast Carcinoma and Its Correlation
More informationFAQs for UK Pathology Departments
FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have
More informationImmunohistochemistry on Fluid Specimens: Technical Considerations
Immunohistochemistry on Fluid Specimens: Technical Considerations Blake Gilks Dept of Pathology University of British Columbia, Vancouver, BC, Canada Disclosures None Learning Objectives At the end of
More informationA Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer
Elmer ress Original Article World J Oncol. 2017;8(3):71-75 A Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer Hui Hu a, Wei Wei a, Xin Yi a, Ling Xin
More informationSystem-wide Ownership Group: Allina Health Breast Program Committee. Hospital Division Quality Council: August 2018
Oncology Clinical Service Line System-wide Consensus Guidelines: Evaluation and Management of Breast Lumpectomy and Mastectomy Specimens by Surgeons and Pathologists These guidelines apply to clinical
More informationUtility of Adequate Core Biopsy Samples from Ultrasound Biopsies Needed for Today s Breast Pathology
Utility of Adequate Core Biopsy Samples from Ultrasound Biopsies Needed for Today s Breast Pathology Ugur Ozerdem, M.D. 1 Abstract Background: There is a paradigm shift in breast biopsy philosophy. In
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationRecent advances in breast cancers
Recent advances in breast cancers Breast cancer is a hetrogenous disease due to distinct genetic alterations. Similar morphological subtypes show variation in clinical behaviour especially in response
More informationCANCER. Clinical Validation of Breast Cancer Predictive Markers
Clinical Validation of Breast Cancer Predictive Markers David Hicks, MD Loralee McMahon, MS, HTL(ASCP) CANCER The human body is composed of billions of highly regulated cells Cancer cells no longer respond
More informationKristen E. Muller, DO, Jonathan D. Marotti, MD, Vincent A. Memoli, MD, Wendy A. Wells, MD, and Laura J. Tafe, MD
AJCP / Original Article Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing Increase in Equivocal Results and Utility of Reflex Immunohistochemistry
More informationNext-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry
Nat Met, April 2014 Nat Med, April 2014 Next-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry Journal Club Timo Böge Overview Introduction Conventional Immunohistochemistry
More informationGuideline. Associated Documents ASCO CAP 2018 GUIDELINES and SUPPLEMENTS -
Guideline Subject: ASCO CAP 2018 HER2 Testing for Breast Cancer Guidelines - Recommendations for Practice in Australasia Approval Date: December 2018 Review Date: December 2022 Review By: HER2 testing
More informationNordiQC External Quality Assurance in Immunohistochemistry
NordiQC External Quality Assurance in Immunohistochemistry Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark AALBORG (~ 200.000 inhabitants)
More informationProstate Immunohistochemistry. Literature Interpretation: Caveats. Must be aware of staining pattern of antibody in the relevant tissue
IHC Interpretation: General Principles (1) Prostate Immunohistochemistry Murali Varma Cardiff, UK wptmv@cf.ac.uk Sarajevo Nov 2013 Must be aware of staining pattern of antibody in the relevant tissue Nuclear/cytoplasmic/membranous
More informationXXV Congreso de la Sociedad Española de Anatomía Patológica y División Española de la International Academy of Pathology
XXV Congreso de la Sociedad Española de Anatomía Patológica y División Española de la International Academy of Pathology NUEVOS FENOTIPOS DEL CÁNCER DE MAMA: NUEVOS PROBLEMAS PARA EL PATÓLOGO? Tienen actualmente
More informationInterpretation of Breast Pathology in the Era of Minimally Invasive Procedures
Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine Jacksonville Medical Director, UF Health Breast Center Chief of Pathology
More informationDepartment of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA 2
Hindawi Publishing Corporation Pathology Research International Volume 2012, Article ID 947041, 7 pages doi:10.1155/2012/947041 Clinical Study The Effect of Cold Ischemia Time and/or Formalin Fixation
More informationSingle and Multiplex Immunohistochemistry
Single and Multiplex Immunohistochemistry Steve Westra, BS Reagent Product Specialist Leica Biosystems IHC Theory Polyclonal vs Monoclonal Polyclonal reagents Detect a multitude of epitopes Batch to batch
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationISPUB.COM. C Choccalingam, L Rao INTRODUCTION ESTROGEN AND PROGESTERONE RECEPTORS
ISPUB.COM The Internet Journal of Pathology Volume 13 Number 1 Learning Experience In Immunohistochemical Reporting Of Breast Cancer At A Rural Tertiary Hospital In India: A Comparison In Initial And Reviewed
More informationGOALS AND OBJECTIVES BREAST PATHOLOGY
GOALS AND OBJECTIVES BREAST PATHOLOGY LEVEL: PGY2, PGY3, PGY5 A number of these rotations are introductory in nature, as they are major subspecialties, and are followed by two more blocks in PGY-3, during
More informationEstrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
Journal of Bangladesh College of Physicians and Surgeons Vol. 28, No. 3, September 2010 Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
More informationImmunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
Breast Cancer Vol. 14 No. 1 January 2007 Original Article Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
More informationHer-2/neu expression and its correlation with ER status and various clinicopathological parameters
Original Research Article DOI: 10.5958/2394-6792.2016.00106.X Her-2/neu expression and its correlation with ER status and various clinicopathological parameters Kriti Chauhan 1,*, Monika Garg 2, Abhimanyu
More informationProduct Introduction. Product Codes: HCL029, HCL030 and HCL031. Issue
Product Introduction Product Codes: HCL029, HCL030 and HCL031 Issue 1. 180510 Contents Introduction to Estrogen Receptor 2 ER immunohistochemistry 3 Quality control 5 Cell lines as controls 6 Estrogen
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More informationMinimizing Errors in Diagnostic Pathology
Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville Medical Director, Shands Jacksonville Breast Health Center
More informationLIST OF ORGANS FOR HISTOPATHOLOGICAL ANALYSIS:!! Neural!!!!!!Respiratory:! Brain : Cerebrum,!!! Lungs and trachea! Olfactory, Cerebellum!!!!Other:!
LIST OF ORGANS FOR HISTOPATHOLOGICAL ANALYSIS:!! Neural!!!!!!Respiratory:! Brain : Cerebrum,!!! Lungs and trachea! Olfactory, Cerebellum!!!!Other:! Spinal cord and peripheral nerves! Eyes, Inner ear, nasal
More informationPepsin Solution ready-to-use
SIE HABEN DIE VISION, WIR HABEN DIE SUBSTANZ. Pepsin Solution Single component Pepsin Solution: only one component refrigerator stable Pepsin is a commonly used digestive enzyme for immunohistochemical
More informationThe Effect of Delay in Fixation, Different Fixatives, and Duration of Fixation in Estrogen and Progesterone Receptor Results in Breast Carcinoma
Anatomic Pathology / Fixation Effects on ER and PR in Breast Cancer The Effect of Delay in Fixation, Different Fixatives, and Duration of Fixation in Estrogen and Progesterone Receptor Results in Breast
More informationA COMPARISON OF THE EFFECT OF COMMERCIAL
African Journal of Cellular Pathology 6:1-5 (016) The Official Journal of the Society for Cellular Pathology Scientists of Nigeria www.ajcpath.com A COMPARISON OF THE EFFECT OF COMMERCIAL ph BUFFERS ON
More informationCorrelation Between GATA-3, Ki67 and p53 Expressions to Histopathology Grading of Breast Cancer in Makassar, Indonesia
Cancer Research Journal 2016; 4(3): 43-47 http://www.sciencepublishinggroup.com/j/crj doi: 10.11648/j.crj.20160403.11 ISSN: 2330-8192 (Print); ISSN: 2330-8214 (Online) Correlation Between GATA-3, Ki67
More informationQuality Assurance and Quality Control in the Pathology Dept.
Quality Assurance and Quality Control in the Pathology Dept. Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 2 nd IBDC, 9 th February, 2012 Pathology as
More informationEstrogen receptor (ER)
Material The slide to be stained for ER comprised: Assessment Run B26 2018 Estrogen receptor (ER) No. Tissue ER-positivity* ER-intensity* 1. Uterine cervix 80-90% Moderate to strong 2. Tonsil 1-5% Weak
More informationMolecular classification of breast cancer implications for pathologists. Sarah E Pinder
Molecular classification of breast cancer implications for pathologists Sarah E Pinder Courtesy of CW Elston Histological types Breast Cancer Special Types 17 morphological special types 25-30% of all
More informationSurgical Pathology Issues of Practical Importance
Surgical Pathology Issues of Practical Importance Anne Moore, MD Medical Oncology Syed Hoda, MD Surgical Pathology The pathologist is central to the team approach needed to manage the patient with breast
More informationReceived 04 November 2008; Accepted in revision 09 January 2009; Available online 20 January 2009
Int J Clin Exp Pathol (2009) 2, 476-480 www.ijcep.com/ijcep811001 Original Article Immunohistochemical Detection of Estrogen and Progesterone Receptor and HER2 Expression in Breast Carcinomas: Comparison
More informationHER2 ISH (BRISH or FISH)
Assessment Run H14 2018 HER2 ISH (BRISH or FISH) Material Table 1. Content of the multi-block used for the NordiQC HER2 ISH assessment, run H14 HER2 IHC* IHC score Dual - SISH** FISH*** FISH*** HER2/chr17
More informationBreast Cancer Diversity Various Disease Subtypes Clinical Diversity
Breast Cancer Predictive Factor Testing: The Challenge and Importance of Standardizing Pre- Analytic Variables David G. Hicks MD Professor of Pathology & Laboratory Medicine Director of Surgical Pathology
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationCOMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME
COMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME Maria Lunardi MD Anatomic Pathology Fracastoro Hospital San Bonifacio, Verona -Italy HER2-neu
More informationPathology Report Patient Companion Guide
Pathology Report Patient Companion Guide Breast Cancer - Understanding Your Pathology Report Pathology Reports can be overwhelming. They contain scientific terms that are unfamiliar and might be a bit
More informationClinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy
Case Series Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy Ling Xu 1*, Fang Li 1,2*, Yinhua Liu 1, Xuening Duan 1, Jingming Ye 1,
More informationHER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer
P A T H O L O G Y HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer FROM CERTAINTY COMES TRUST For in vitro diagnostic use HER2 CISH pharmdx Kit HER2 CISH pharmdx Kit is intended for dual-color
More informationLayered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue
Page 1 The need for multiplex detection of tissue biomarkers. There is a constant and growing demand for increased biomarker analysis in human tissue specimens. Analysis of tissue biomarkers is key to
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationWhat kind of material should we use for ICC in our daily routine. Torill Sauer Department of Pathology, Akershus University Hospital
What kind of material should we use for ICC in our daily routine Torill Sauer Department of Pathology, Akershus University Hospital Diversity of preparing cytological material Cell block Direct smears
More informationCME/SAM. Abstract. Anatomic Pathology / HER2/neu Results in Breast Cancer
Anatomic Pathology / HER2/neu Results in Breast Cancer Effect of Ischemic Time, Fixation Time, and Fixative Type on HER2/neu Immunohistochemical and Fluorescence In Situ Hybridization Results in Breast
More informationKi-67 is a biological tumor marker that reflects tumor
Evaluation of Ki-67 Index in Core Needle Biopsies and Matched Breast Cancer Surgical Specimens Soomin Ahn, MD; Junghye Lee, MD; Min-Sun Cho, MD, PhD; Sanghui Park, MD, PhD; Sun Hee Sung, MD, PhD Context.
More informationINTRODUCTION TO PATHOLOGICAL TECHNIQUES. 1. Types of routine biopsy procedures 2. Special exams (IHC, FISH)
INTRODUCTION TO PATHOLOGICAL TECHNIQUES 1. Types of routine biopsy procedures 2. Special exams (IHC, FISH) Biopsy-Indications Diffuse/multifocal lesions (neoplastic, inflammatory, etc) Etiology of the
More informationCost Effectiveness of Manual Tissue Microarray Technique in Diagnostic Immunohistochemistry
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 17, Issue 2 Ver. 1 February. (2018), PP 43-48 www.iosrjournals.org Cost Effectiveness of Manual Tissue
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationSMH (Myosin, smooth muscle heavy chain)
Material The slide to be stained for SMH comprised: Assessment Run 50 2017 SMH (Myosin, smooth muscle heavy chain) 1.Tonsil, 2. Esophagus, 3. Breast hyperplasia, 4. Breast ductal carcinoma in situ (DCIS),
More informationVersion 2 of these Guidelines were drafted in response to published updated ASCO/CAP HER2 test Guideline Recommendations-
Introduction: These guidelines represent systematically developed statements to assist in the provision of quality assured HER2 testing in breast and gastric/ gastro-oesophageal carcinoma. They are based
More informationBreast pathology. 2nd Department of Pathology Semmelweis University
Breast pathology 2nd Department of Pathology Semmelweis University Breast pathology - Summary - Benign lesions - Acute mastitis - Plasma cell mastitis / duct ectasia - Fat necrosis - Fibrocystic change/
More informationAssessment Run B HER-2 IHC. HER-2/chr17 ratio**
Assessment Run B2 20 HER-2 IHC Material The slide to be stained for HER-2 comprised the following 5 tissues: IHC HER-2 Score* (0, +, 2+,3+) FISH HER-2/chr7 ratio**. Breast ductal carcinoma 0..3 2. Breast
More informationBreast cancer: Antibody selection, protocol optimzation controls and EQA
Breast cancer: Antibody selection, protocol optimzation controls and EQA Workshop in Diagnostic Immunohistochemistry Oud St. Jan/ Old St. John Brugge (Bruges), Belgium June 13th 15nd 2018 Rasmus Røge,
More informationNeuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical parameters
& 2004 USCAP, Inc All rights reserved 0893-3952/04 $25.00 www.modernpathology.org Neuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical
More informationClaudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More informationPapillary Lesions of the Breast
Papillary Lesions of the Breast Laura C. Collins, M.D. Associate Professor of Pathology Associate Director, Division of Anatomic Pathology Beth Israel Deaconess Medical Center and Harvard Medical School
More informationEstrogen receptor (ER)
Material The slide to be stained for ER comprised: Assessment B25 208 Estrogen receptor (ER) No. Tissue ER-positivity* ER-intensity*. Uterine cervix 80-90% Moderate to strong 2. Tonsil < 2-5% Weak to strong
More informationCarcinoembryonic antigen (CEA)
Assessment Run 37 2013 Carcinoembryonic antigen (CEA) Material The slide to be stained for CEA comprised: 1. Appendix, 2. Liver, 3-4. Colon adenocarcinoma, 5. Urothelial carcinoma All tissues were fixed
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationBreast cancer diagnostic solutions Deliver diagnostic confidence
Breast cancer diagnostic solutions Deliver diagnostic confidence 2 Breast cancer diagnostic solutions Roche Tissue Diagnostics is committed to improving outcomes in breast cancer Breast cancer...the most
More informationQuantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer
Quantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer Guideline from the College of American Pathologists Early Online Release Publication: Archives of Pathology & Laboratory Medicine
More informationCorporate Medical Policy
Corporate Medical Policy Microarray-based Gene Expression Testing for Cancers of Unknown File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microarray-based_gene_expression_testing_for_cancers_of_unknown_primary
More informationN Purpose. To develop a guideline to improve the. Special Article
Special Article American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
More informationGastric Carcinoma with Lymphoid Stroma: Association with Epstein Virus Genome demonstrated by PCR
Gastric Carcinoma with Lymphoid Stroma: Association with Epstein Virus Genome demonstrated by PCR Pages with reference to book, From 305 To 307 Irshad N. Soomro,Samina Noorali,Syed Abdul Aziz,Suhail Muzaffar,Shahid
More informationThe Expression of Basal Cytokeratins in Breast Cancers
Global Journal of Medical Research: C Microbiology and Pathology Volume 17 Issue 2 Version 1.0 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online
More informationThe Oncotype DX Assay A Genomic Approach to Breast Cancer
The Oncotype DX Assay A Genomic Approach to Breast Cancer Pathology: 20 th and 21 st Century Size Age Phenotype Nodal status Protein/Gene Genomic Profiling Prognostic & Predictive Markers Used in Breast
More informationImmunohistochemical studies (ER & Ki-67) in Proliferative breast lesions adjacent to malignancy
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 13, Issue 3 Ver. IV. (Mar. 2014), PP 84-89 Immunohistochemical studies (ER & Ki-67) in Proliferative
More informationHandout for Dr Allison s Lectures on Grossing Breast Specimens:
Handout for Dr Allison s Lectures on Grossing Breast Specimens: Dr. Kimberly H. Allison Director of Breast Pathology and Breast Pathology Fellowship Director of Residency Training in Pathology Stanford
More informationPapillary Lesions of the Breast A Practical Approach to Diagnosis. (Arch Pathol Lab Med. 2016;140: ; doi: /arpa.
Papillary Lesions of the Breast A Practical Approach to Diagnosis (Arch Pathol Lab Med. 2016;140:1052 1059; doi: 10.5858/arpa.2016-0219-RA) Papillary lesions of the breast Span the spectrum of benign,
More informationThe College of American Pathologists (CAP) offers these
CAP Laboratory Improvement Programs Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Endometrium Teri A. Longacre, MD; Russell Broaddus, MD, PhD; Linus
More informationACRIN 6666 Therapeutic Surgery Form
S1 ACRIN 6666 Therapeutic Surgery Form 6666 Instructions: Complete a separate S1 form for each separate area of each breast excised with the intent to treat a cancer (e.g. each lumpectomy or mastectomy).
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority
Quality ID #449 (NQF 1857): HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted Therapies National Quality Strategy Domain: Efficiency and Cost Reduction Meaningful
More informationAssessment Run B HER2 IHC
Assessment Run B24 2017 HER2 IHC Material The slide to be stained for HER2 comprised the following 5 materials: IHC: HER2 Score* (0, 1+, 2+, 3+) FISH: HER2 gene/chr 17 ratio** 1. Breast carcinoma, no.
More informationAssessment performed on Tuesday, July 29, 2014, at Lions Gate Hospital, North Vancouver
Assessors report for ciqc Run 37: BRAF V600E (April 2014) Assessors: B Gilks, R Wolber, K Ung, P Tavassoli, J Garratt and J Won (recorder) Assessment performed on Tuesday, July 29, 2014, at Lions Gate
More informationAssessment Run B HER2 IHC
Assessment Run B26 208 HER2 IHC Material The slide to be stained for HER2 comprised the following 5 materials: IHC: HER2 Score* (0, +, 2+, 3+) FISH: HER2 gene/chr 7 ratio**. Breast carcinoma, no. 2+..3
More informationPotential Value of Hormone Receptor Assay in Carcinoma In Situ of Breast
Potential Value of Hormone Receptor Assay in Carcinoma In Situ of Breast ROBERT BARNES, M.D. AND SHAHLA MASOOD, M.D. The estrogen receptor (ER) expression of invasive breast cancer has been extensively
More informationAssessment performed on Friday, September 18, 2015, at Vancouver General Hospital
Assessors report for ciqc Run 49: ATRX (June 2015) Assessors: S Yip and J Won (recorder) Assessment performed on Friday, September 18, 2015, at Vancouver General Hospital Background The combined application
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationMolecular Characterization of Breast Cancer: The Clinical Significance
Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationData Supplement 1: 2013 Update Rationale and Background Information
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology /College of American Pathologists Clinical Practice Guideline Update (edited
More informationPapillary Lesions of the breast
Papillary Lesions of the breast Emad Rakha Professor of Breast Pathology The University of Nottingham Papillary lesions of the breast are a heterogeneous group of disease, which are characterised by neoplastic
More information